Agenus Inc. (AGEN) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

10/25

Growth 3 Margin 1 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

10
AGEN Q2 2025: $75M Zydus Deal Reshapes Balance Sheet and Accelerates CRC Trial Path
August 27, 2025
7
Agenus (AGEN) Q1 2025: BOT/BAL Advances with New Leadership and Strategic Capital Options
May 12, 2025
9
Agenus (AGEN) Q4 2024: Operational Burn Cuts to $50M Fuel Botensilimab’s Transformative CRC Potential
March 11, 2025
AGEN Q3 2024: Cash Burn Drops 29% as BotVal Data Drives Strategic Asset Monetization
November 12, 2024
AGEN Q1 2024: $100M Royalty Financing Secured, Accelerating Botensilimab Path to Approval
May 07, 2024
AGEN Q4 2023: $250M Partner Milestone Sets Stage for Accelerated Oncology Expansion
March 14, 2024
9
AGEN (AGEN) Q3 2023: $200M Non-Dilutive Cash Plan Extends Runway as BLA Filing Nears
November 07, 2023
AGEN (AGEN) Q1 2023: Botansilumab Response Rates Reach 50% in Refractory Solid Tumors, Fast Track Designation Advances Pipeline
May 09, 2023
AGEN Q4 2022: Botensilimab-Driven 23% ORR in MSS-CRC Signals Potential Paradigm Shift
March 14, 2023

Browse all companies